Mario Angelico

Mario Angelico

Auto-generated profile, based on publicly available information

Mario Angelico

Hepatology Unit, University of Rome Tor Vergata, Rome, Italy

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1986 in Medical Hypotheses
Verified
Journal Article
Closed access
AAAdolfo Francesco Attili
Adolfo Francesco Attili
MAM. Angelico
M. Angelico
ACA. Cantafora
A. Cantafora
DADomenico Alvaro
Domenico Alvaro
LCL. Capocaccia
L. Capocaccia

1 January 2002 in Hepatology
Verified
Journal Article
Open access
PDF file
MAMario Angelico
Mario Angelico
DPDaniele Di Paolo
Daniele Di Paolo
MTMassimo O. Trinito
Massimo O. Trinito
APAlessandra Petrolati
Alessandra Petrolati
AAAntonio Araco
Antonio Araco
GTGiuseppe Tisone
Giuseppe Tisone
Long-term immunoprophylaxis with anti-HBs immunoglobulins (HBIg) is used to prevent hepatitis B (HBV) reinfection after liver transplantation for HBV-related cirrhosis. This approach is highly expensive. A recent report proposed posttransplant HBV vaccination with a reinforced schedule as an alternative strategy to allow HBIg discontinuation. We investigated the efficacy of a reinforced triple course of HBV vaccination in 17 patients transplanted for HBsAg—positive cirrhosis 2 to 7 years earlier. The first cycle consisted of 3 double intramuscular doses (40 μg) of recombinant vaccine at month 0, 1, and 2, respectively. This was followed, in nonresponders, by a second cycle of 6 intradermal 10 μg doses every 15 days. All nonresponders then received a third cycle identical to the first one. Vaccination started 4.5 months after HBIg discontinuation, and lamivudine (100 mg/day) was given throughout the study. All patients were seronegative for HBsAg and HBV-DNA (by PCR) and positive for anti-HBe, and 7 were positive for anti-HDV. After the first cycle one patient (#5, 53 years old, male) developed an anti-HBs titer of 154 IU/L, another (#12) reached a titer of 20 IU/L and the remainder had titers <10 IU/L. At month 7, patient #5 reached a titer of 687 IU/L. After the second cycle only one additional patient (#9) had a slight response (an anti-HBs titer of 37 IU/L). After the third cycle patient #9 rose to an anti-HBs titer of 280 IU/L, patient #12 dropped to 10 IU/L, and no other patient responded. In conclusion, a highly reinforced HBV vaccination program is effective only in a few patients who had liver transplants for HBV—related cirrhosis.

1 November 1997 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
MAM Angelico
M Angelico
LCL Carli
L Carli
CPC Piat
C Piat
SGS Gentile
S Gentile
LCL Capocaccia
L Capocaccia

1 April 2006 in Journal of Hepatology
Verified
Journal Article
Closed access
GTGiuseppe Tisone
Giuseppe Tisone
GOGiuseppe Orlando
Giuseppe Orlando
ACAndrea Cardillo
Andrea Cardillo
GPGiampiero Palmieri
Giampiero Palmieri
Tommaso Maria ManziaTommaso Maria Manzia
Tommaso Maria Manzia
MAMario Angelico
Mario Angelico

21 November 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
RSRomina Salpini
Romina Salpini
LCLuna Colagrossi
Luna Colagrossi
MBMaria Concetta Bellocchi
Maria Concetta Bellocchi
MSMatteo Surdo
Matteo Surdo
CBChristina Becker
Christina Becker
VSValentina Svicher
Valentina Svicher
Hepatitis B virus (HBV) reactivation during immunosuppression can lead to severe acute hepatitis, fulminant liver failure, and death. Here, we investigated hepatitis B surface antigen (HBsAg) genetic features underlying this phenomenon by analyzing 93 patients: 29 developing HBV reactivation and 64 consecutive patients with chronic HBV infection (as control). HBsAg genetic diversity was analyzed by population‐based and ultradeep sequencing (UDS). Before HBV reactivation, 51.7% of patients were isolated hepatitis B core antibody (anti‐HBc) positive, 31.0% inactive carriers, 6.9% anti‐HBc/anti‐HBs (hepatitis B surface antibody) positive, 6.9% isolated anti‐HBs positive, and 3.4% had an overt HBV infection. Of HBV‐reactivated patients, 51.7% were treated with rituximab, 34.5% with different chemotherapeutics, and 13.8% with corticosteroids only for inflammatory diseases. In total, 75.9% of HBV‐reactivated patients (vs. 3.1% of control patients; P < 0.001) carried HBsAg mutations localized in immune‐active HBsAg regions. Of the 13 HBsAg mutations found in these patients, 8 of 13 (M103I‐L109I‐T118K‐P120A‐Y134H‐S143L‐D144E‐S171F) reside in a major hydrophilic loop (target of neutralizing antibodies [Abs]); some of them are already known to hamper HBsAg recognition by humoral response. The remaining five (C48G‐V96A‐L175S‐G185E‐V190A) are localized in class I/II–restricted T‐cell epitopes, suggesting a role in HBV escape from T‐cell‐mediated responses. By UDS, these mutations occurred in HBV‐reactivated patients with a median intrapatient prevalence of 73.3% (range, 27.6%‐100%) supporting their fixation in the viral population as a predominant species. In control patients carrying such mutations, their median intrapatient prevalence was 4.6% (range, 2.5%‐11.3%; P < 0.001). Finally, additional N‐linked glycosylation (NLG) sites within the major hydrophilic loop were found in 24.1% of HBV‐reactivated patients (vs. 0% of chronic patients; P < 0.001); 5 of 7 patients carrying these sites remained HBsAg negative despite HBV reactivation. NLG can mask immunogenic epitopes, abrogating HBsAg recognition by Abs. Conclusion: HBV reactivation occurs in a wide variety of clinical settings requiring immune‐suppressive therapy, and correlates with HBsAg mutations endowed with enhanced capability to evade immune response. This highlights the need for careful patient monitoring in all immunosuppressive settings at reactivation risk and of establishing a prompt therapy to prevent HBV‐related clinical complications. (Hepatology 2015;61:823–833)

1 May 2002 in Hepatology
Verified
Journal Article
Open access
PDF file
GAGianfranco Alpini
Gianfranco Alpini
LBLeonardo Baiocchi
Leonardo Baiocchi
SGShannon Glaser
Shannon Glaser
YUYoshiyuki Ueno
Yoshiyuki Ueno
MMMarco Marzioni
Marco Marzioni
GLGene LeSage
Gene LeSage
Accumulating bile acids (BA) trigger cholangiocyte proliferation in chronic cholestasis. The aim of this study was to determine if ursodeoxycholate (UDCA) or tauroursodeoxycholate (TUDCA) chronic feeding prevents the increased cholangiocyte growth and secretion in bile duct-ligated (BDL) rats, if UDCA and TUDCA effects are associated with increased cholangiocyte apoptosis, and to determine if this inhibition is dependent on increased intracellular Ca2+ ([Ca2+]i) and activation of protein kinase C (PKC) alpha. Immediately after BDL, rats were fed UDCA or TUDCA (both 275 μmol/d) for 1 week. We determined the number of bile ducts in liver sections, cholangiocyte proliferation (by measurement of H3 histone and proliferating cellular nuclear antigen in isolated cholangiocytes), and ductal secretion. In purified cholangiocytes from 1-week BDL rats, we evaluated if UDCA and TUDCA directly inhibit cholangiocyte proliferation and secretin-stimulated adenosine 3', 5'-monophosphate levels. We determined if UDCA and TUDCA activate PKC, increase [Ca2+]i, and alter the apical BA transporter (ABAT) expression in cholangiocytes. UDCA and TUDCA inhibited in vivo the cholangiocyte proliferation, secretion, and ABAT expression. In vitro UDCA and TUDCA inhibition of cholangiocyte growth and secretion required increased [Ca2+]i and PKC alpha. In conclusion, activation of Ca2+-dependent PKC alpha is required for UDCA and TUDCA inhibition of cholangiocyte growth and secretion. Reduced cholangiocyte ABAT may decrease endogenous BA stimulation of cholangiocyte growth and secretion.